Events, Pharmaceuticals and Psychedelic therapy

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Events

Pharmaceuticals

Psychedelic therapy

One Person’s Journey from Celebrity Medical Model Advocate to Skeptic: An Interview with Rose Cartwright

Mad in America

NOVEMBER 6, 2024

Dhar: Eventually you found the trauma model that talked about extreme childhood stress events, and it explained a lot of your suffering. You write that you worry about how psychedelics are getting co-opted by pharmaceutical industries. There wasn’t much space for another way of seeing the problem of obsessions and compulsions.

Trauma and the brain

Trauma and the brain Poverty and mental health Psychedelic therapy Childhood trauma

A Win for Science, with Profound Implications for Industry: FDA Rejects MDMA

Mad in America

AUGUST 14, 2024

L ykos Therapeutics experienced a double blow this week, with the FDA’s rejection of their proprietary MDMA-assisted therapy for PTSD and the retraction of three articles on MDMA’s supposed efficacy. Moreover, Lykos is a small company bringing it to market, one that emerged out of a psychedelic research nonprofit (MAPS).

Pharmaceuticals

Pharmaceuticals Nonprofits Psychedelic therapy

Mental Health Clinicians

One Person’s Journey from Celebrity Medical Model Advocate to Skeptic: An Interview with Rose Cartwright

A Win for Science, with Profound Implications for Industry: FDA Rejects MDMA

Stay Connected